LifeStance Health Group, Inc. (LFST) Stock Forecast
LFST analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.45 / 5 from 11 analysts
- Price target
- $14.40 average of analyst targets
- Upside to target
- +22.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.03
- 52-week range
- $4.81 – $13.38
LFST analyst ratings
11 analystsNumber of analysts at each rating.
LFST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LFST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.08 | $0.07 | $0.10 | $0.01 | +480.9% | 5 |
| Current fiscal year (2026) | $0.36 | $0.32 | $0.39 | $0.18 | +97.1% | 5 |
| Next fiscal year (2027) | $0.43 | $0.38 | $0.51 | $0.36 | +19.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LFST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $431.6M | $426.0M | $436.8M | +18.6% | 9 |
| Current fiscal year (2026) | $1.71B | $1.70B | $1.72B | +20.0% | 10 |
| Next fiscal year (2027) | $1.96B | $1.92B | $1.99B | +14.5% | 10 |
LFST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LFST revenue: reported and forecast
LFST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.07 | $0.07 | $0.10 | $0.10 | $0.08 | +14.0% | 0 up · 1 down |
| Current fiscal year (2026) | $0.31 | $0.31 | $0.40 | $0.40 | $0.36 | +15.4% | 0 up · 1 down |
| Next fiscal year (2027) | $0.39 | $0.39 | $0.53 | $0.53 | $0.43 | +9.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LFST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LFST beat in 9 of 12.
What analysts expect from LFST
11 analysts cover LifeStance Health; their consensus rating is buy (4.45 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.40, 22.7% above the latest close of $11.74. Analysts expect earnings of $0.36 per share for 2026, +97.1% from a year earlier. For 2027 the average estimate is $0.43 per share on revenue of $2.0 billion. LifeStance Health beat the EPS estimate in 9 of the last 12 quarters.
Related: LFST income statement, LFST key metrics, LFST chart. See the LFST stock overview for the latest quote and news.
LFST forecast FAQ
What is LifeStance Health's price target?
The average analyst price target for LifeStance Health is $14.40, 22.7% above the latest close of $11.74.
Is LifeStance Health a buy, hold or sell?
Of 11 analysts covering LifeStance Health, 7 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is LifeStance Health's EPS forecast?
Analysts forecast $0.36 per share for 2026 (range $0.32 to $0.39); for 2027 the estimate is $0.43.
What is LifeStance Health's revenue forecast?
The average revenue estimate for 2026 is $1.7 billion, growth of 20.0%; for 2027 it is $2.0 billion.
When does LifeStance Health report earnings?
LifeStance Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $0.03.
Does LifeStance Health usually beat earnings estimates?
LifeStance Health reported EPS at or above the analyst estimate in 9 of the last 12 quarters.